{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:39:52Z","timestamp":1773369592621,"version":"3.50.1"},"reference-count":30,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>(1) Background: There are limited data regarding the efficacy of convalescent plasma (CP) in critically ill patients admitted to the intensive care unit (ICU) due to coronavirus disease 2019 (COVID-19). We aimed to determine whether CP is associated with better clinical outcome among these patients. (2) Methods:\u00a0A\u00a0retrospective single-center study including adult patients with laboratory-confirmed SARS-CoV-2 infection admitted to the ICU for acute respiratory failure. The primary outcome was time to clinical improvement, within 28 days, defined as patient discharged alive or reduction of 2 points on a 6-point disease severity scale. (3)\u00a0Results:\u00a0Overall, 110 COVID-19 patients were admitted. Thirty-two patients (29%) received CP; among them, 62.5% received at least one CP with high neutralizing antibody titers (\u22651:160). Clinical improvement occurred within 28 days in 14 patients (43.7%) of the CP group vs. 48 patients (61.5%) in the non-CP group (hazard ratio (HR): 0.75 (95% CI: 0.41\u20131.37), p = 0.35). After adjusting for potential confounding factors, CP was not independently associated with time to clinical improvement (HR: 0.53 (95% CI: 0.23\u20131.22), p = 0.14). Additionally, the average treatment effects of CP, calculated using the inverse probability weights (IPW), was not associated with the primary outcome (\u22120.14 days (95% CI: \u22123.19\u20132.91 days), p = 0.93). Hospital mortality did not differ between CP and non-CP groups (31.2% vs. 19.2%, p = 0.17, respectively). Comparing CP with high neutralizing antibody titers to the other group yielded the same findings. (4) Conclusions: In this study of life-threatening COVID-19 patients, CP was not associated with time to clinical improvement within 28 days, or hospital mortality.<\/jats:p>","DOI":"10.3390\/jcm10102113","type":"journal-article","created":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:28:36Z","timestamp":1620962916000},"page":"2113","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Convalescent Plasma Efficacy in Life-Threatening COVID-19 Patients Admitted to the ICU: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"10","author":[{"given":"Mohamed","family":"Abuzakouk","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates"},{"name":"Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Saleh","sequence":"additional","affiliation":[{"name":"Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Algora","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA"},{"name":"Pathology and Laboratory Medicine Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Nusair","sequence":"additional","affiliation":[{"name":"Medical Subspecialties Institute-Infectious Diseases, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jawahir","family":"Alameri","sequence":"additional","affiliation":[{"name":"Education Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatema","family":"Alshehhi","sequence":"additional","affiliation":[{"name":"Education Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Alkhaja","sequence":"additional","affiliation":[{"name":"Education Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Badr","sequence":"additional","affiliation":[{"name":"Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Abdallah","sequence":"additional","affiliation":[{"name":"Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"De Oliveira","sequence":"additional","affiliation":[{"name":"Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashraf","family":"Nadeem","sequence":"additional","affiliation":[{"name":"Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeldho","family":"Varghese","sequence":"additional","affiliation":[{"name":"Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dnyaseshwar","family":"Munde","sequence":"additional","affiliation":[{"name":"Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shameen","family":"Salam","sequence":"additional","affiliation":[{"name":"Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baraa","family":"Abduljawad","sequence":"additional","affiliation":[{"name":"Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussam","family":"Elkambergy","sequence":"additional","affiliation":[{"name":"Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Wahla","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Taha","sequence":"additional","affiliation":[{"name":"Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamil","family":"Dibu","sequence":"additional","affiliation":[{"name":"Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Bayrlee","sequence":"additional","affiliation":[{"name":"Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadi","family":"Hamed","sequence":"additional","affiliation":[{"name":"Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laila","family":"AbdelWareth","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadeem","family":"Rahman","sequence":"additional","affiliation":[{"name":"Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Guzman","sequence":"additional","affiliation":[{"name":"Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6372-7360","authenticated-orcid":false,"given":"Jihad","family":"Mallat","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA"},{"name":"Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates"},{"name":"Faculty of Medicine, Normandy University, UNICAEN, ED 497, 1400 Caen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,14]]},"reference":[{"key":"ref_1","unstructured":"(2021, March 01). WHO Coronavirus Disease Dashboard. Available online: https:\/\/covid19.who.int."},{"key":"ref_2","unstructured":"(2021, March 01). Covid19 Hospitalization Forcasts: Cdc.gov, Available online: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/cases-updates\/hospitalizations-forecasts.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19\u2014Prelimiary report: Reply","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"The RECOVERY Collaborative Group, Horby, P., Lim, W.S., and Emberson, J.R. (2021). Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med., 384, 693\u2013704.","DOI":"10.1056\/NEJMoa2021436"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","article-title":"Meta-analysis. convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment?","volume":"145","author":"Luke","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/jac\/dki346","article-title":"Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital","volume":"56","author":"Yeh","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3201\/eid2209.151164","article-title":"Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia","volume":"22","author":"Arabi","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Joyner, M., Senefeld, J., Mills, J.R., Johnson, P.W., Theel, E.S., Wiggins, C.C., Bruno, K.A., Klompas, A.M., Lesser, E.R., and Kunze, K.L. (2020). Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience. MedRxiv.","DOI":"10.1101\/2020.08.12.20169359"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa2031893","article-title":"Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19","volume":"384","author":"Joyner","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa2033700","article-title":"Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults","volume":"384","author":"Libster","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"m3939","DOI":"10.1136\/bmj.m3939","article-title":"Convalescent plasma in the management of moderate covid-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial)","volume":"371","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJMoa2031304","article-title":"A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia","volume":"384","author":"Simonovich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical Trial","volume":"324","author":"Li","year":"2020","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1001\/jama.2021.2747","article-title":"Association of Convalescent Plasma Treatment with Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis","volume":"325","author":"Janiaud","year":"2021","journal-title":"JAMA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"630982","DOI":"10.3389\/fmed.2021.630982","article-title":"Effect of Convalescent Plasma in Critically Ill Patients With COVID-19: An Observational Study","volume":"8","author":"Kurtz","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/jmv.26537","article-title":"Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report","volume":"93","author":"Omrani","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Bonelli, F., Sarasini, A., Zierold, C., Calleri, M., Bonetti, A., Vismara, C., Blocki, F.A., Pallavicini, L., Chinali, A., and Campisi, D. (2020). Clinical and Analytical Performance of an Automated Serological Test That Identifies S1\/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively. J. Clin. Microbiol., 58.","DOI":"10.1128\/JCM.01224-20"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jclinepi.2013.01.013","article-title":"Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research","volume":"66","author":"Stuart","year":"2013","journal-title":"J. Clin. Epidemiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/1475-6773.12182","article-title":"Methods for constructing and assessing propensity scores","volume":"49","author":"Garrido","year":"2014","journal-title":"Health Serv. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: Consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"46","author":"Ruan","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.abb8925","article-title":"Cytokine release syndrome in severe COVID-19","volume":"368","author":"Moore","year":"2020","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19","volume":"130","author":"Casadevall","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Gharbharan, A., Jordans, C.C., GeurtsvanKessel, C., den Hollander, J.G., Karim, F., Mollema, F.P., Stalenhoef, J.E., Dofferhoff, A., Ludwig, I., and Koster, A. (2020). Convalescent plasma for COVID-19: A randomized clinical trial. Medrxiv.","DOI":"10.1101\/2020.07.01.20139857"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1172\/JCI140200","article-title":"Early safety indicators of COVID-19 convalescent plasma in 5000 patients","volume":"130","author":"Joyner","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"RECOVERY Collaborative Group (2021). Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet, 397, 1637\u20131645.","DOI":"10.1101\/2021.02.11.21249258"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Misset, B., Hoste, E., Donneau, A.F., Grimaldi, D., Meyfroidt, G., Moutschen, M., Compernolle, V., Gothot, A., Desmecht, D., and Garigliany, M. (2020). A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: The CONFIDENT trial protocol. BMC Pulm. Med., 20.","DOI":"10.1186\/s12890-020-01361-x"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Hamilton, F.W., Lee, T.C., Arnold, D.T., Lilford, R., and Hemming, K. (2021). Is convalescent plasma futile in COVID-19? A Bayesian reanalysis of the RECOVERY randomised controlled trial. MedRxiv.","DOI":"10.1101\/2021.04.01.21254679"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/10\/2113\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:00:38Z","timestamp":1760162438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/10\/2113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,14]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["jcm10102113"],"URL":"https:\/\/doi.org\/10.3390\/jcm10102113","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,14]]}}}